Scientific programs (2016-2024)

Our team's scientific interests are organized around four primary programs:

• Advanced Therapy Medicinal Products (ATMPs), extracellular vesicles and stem cell-based strategies for tissue regeneration,

• Novel therapeutic approaches to restore vascular, metabolic and organ function in disease contexts,

• Double 3D active implants with organized cell organoids to promote neovascularization, model tumors and restore tissue,

• Innovative drug formulations using polymers, lipids and hybrid materials to improve biopharmaceutical properties.

We are particularly focused on:

• developing pharmacological treatments for periodontal and oral bony defects and understanding dental primary failure of eruption (PFE),

• optimizing anti-inflammatory delivery systems,

• engineering isomorphic mouse models of intra-oral implants in collaboration with industry partners,

• targeting endothelial senescence to rejuvenate cardiovascular and vascular health,

• elucidating molecular mechanisms of microvesicle-driven endothelial senescence,

• developing vascularized organ-on-chip and micro/mesofluidic devices for rapid personalized therapeutics,

• establishing preclinical cancer models (PDX, 3D organoids) for drug testing, biomarker discovery and personalized medicine,

• designing innovative colloidal and polymer-based drug delivery systems.

Regenerative Nanomedicine unit INSERM-UNISTRA thrives on interdisciplinary collaboration, merging material science, medicinal chemistry, molecular and cellular biology as well as clinical applications. Our research spans domains including:

• bone and cartilage regeneration,

• periodontal regeneration and anti-inflammatory therapeutics,

• vascular repair in organ dysfunction and transplantation,

• mesofluidic and organoid-based device innovation,

• biogalenics and advanced medicinal chemistry,

• cardio-oncology, metabolic tissue regeneration and precision medicine,

• rare disease research, epidemiology and public health evaluations.

Our laboratory is establishing a comprehensive technological platform to support all 2D and 3D disease models, integrating expertise in cell and molecular biology, histology, in vivo experimentation and personalized therapeutic assessment.

Regenerative Nanomedicine unit INSERM-UNISTRA is at the forefront of regenerative nanomedicine, developing next-generation "living materials" and precision therapies that bridge the gap from bench to bedside.